Adimab, a Lebanon, NH-based biotech firm focused antibody discovery, says it has closed a Series C round of financing from new investors OrbiMed Advisors, Borealis Ventures, and return backers Polaris Venture Partners and SV Live Sciences. Financial details weren’t disclosed. Tillman Gerngross, CEO and co-founder of the company, said in a statement that his company is able to speed the time required to discover antibodies to a matter of weeks.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
